Table 1.
Comparison of oncogenes and tumor suppressor genes (TSGs) on lung SqCC and ADC tumors
| Gene | SqCC | ADC | Type | ||
|---|---|---|---|---|---|
| mRNA, microRNA, and DNA sequencing [12] | Proteomics glycoproteomics | mRNA, microRNA, and DNA sequencing [13] | Proteomics glycoproteomics | ||
| TP53 | + | + | + | NE | Oncogene |
| KRAS | + | − | − | Oncogene | |
| KEAP1 | + | NC | + | ND | Oncogene |
| STK11 | + | ND | − | TSG | |
| EGFR | + | + | + | Oncogene | |
| NF1 | + | ND | ND | TSG | |
| BRAF | + | NC | NC | Oncogene | |
| SETD2 | + | ND | ND | TSG | |
| RBM10 | + | NC | NC | TSG | |
| MGA | + | ND | ND | TSG | |
| MET | + | + | + | Oncogene | |
| ARID1A | + | NC | NC | TSG | |
| PIK3CA | + | Y− | + | − | Oncogene |
| SMARCA4 | + | NC | − | TSG | |
| RB1 | + | NC | + | NC | Oncogene |
| CDKN2A | + | + | + | + | TSG |
| U2AF1 | + | + | Y− | Oncogene | |
| RIT1 | + | − | NC | TSG | |
| NOTCH1 | ND | + | − | TSG | |
| PTEN | NC | + | − | TSG | |
| HLA-A* | + | + | + | Oncogene | |
| NFE2L2 | ND | + | ND | Oncogene | |
| MLL2 | ND | + | ND | TSG | |
| FHIT | NC | NC | Oncogene | ||
| MST1 | NC | − | TSG | ||
| BAD | NC | NC | Oncogene | ||
| RXR | + | ND | Oncogene | ||
| NFκBIA | − | − | TSG | ||
The activation or inhibition is based on quantitative data from proteins and glycoproteins. The analysis was performed using Ingenuity Pathway Analysis (IPA). NC no change, ND not detected, NE no effect, “+” activation or upregulation, “−” inhibition or downregulation, “*” only detected in glycoproteins by SPEG. Gene mutation is compared with studies using mRNA, microRNA, and DNA sequencing on ADC [12] and SqCC [13]